Response to sunitinib malate in advanced alveolar soft part sarcoma

Clinical Cancer Research

Volumn 15, Issue 3, 2009, Pages 1096-1104

  Stacchiotti, Silvia ^a   Tamborini, Elena ^a   Marrari, Andrea ^a   Brich, Silvia ^a   Rota, Sara Arisi ^a   Orsenigo, Marta ^a   Crippa, Flavio ^a   Morosi, Carlo ^a   Gronchi, Alessandro ^a   Pierotti, Marco A ^a   Casali, Paolo G ^a   Pilotti, Silvana ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN KINASE B; PROTEIN RET; PROTEIN S6; PROTEIN TYROSINE KINASE; S6 KINASE; SCATTER FACTOR RECEPTOR; SUNITINIB; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ADULT; ADVANCED CANCER; ALVEOLAR SOFT PART SARCOMA; ANEMIA; ARTICLE; CANCER GROWTH; CLINICAL ARTICLE; ENZYME ACTIVATION; FATIGUE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HYPOTHYROIDISM; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; MALE; NAUSEA AND VOMITING; NEUTROPENIA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; THROMBOCYTOPENIA; TREATMENT RESPONSE; WESTERN BLOTTING;

ADULT; DRUG EVALUATION; FEMALE; HUMANS; INDOLES; MALE; MIDDLE AGED; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; PROTO-ONCOGENE PROTEINS C-AKT; PYRROLES; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; SARCOMA, ALVEOLAR SOFT PART; SIGNAL TRANSDUCTION;

EID: 61549104154     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-2050     Document Type: Article

References (34)

1. Portera CA, Jr., Ho V, Patel SR, et al. Alveolar soft part sarcoma: clinical course and patterns of metastasis in 70 patients treated at a single institution. Cancer 2001; 91:585-91.
2. Ogose A, Yazawa Y, Ueda T, et al. Alveolar soft part sarcoma in Japan: multi-institutional study of 57 patients from the Japanese Musculoskeletal Oncology Group. Oncology 2003;65:7-13.
3. Reichardt P, Lindner T, Pink D, Thuss-Patience PC, Kretzschmar A, Dörken B. Chemotherapy in alveolar soft part sarcomas. What do we know? Eur J Cancer 2003;39:1511-6.
4. Bisogno G, Rosolen A, Carli M. Interferon α for alveolar soft part sarcoma. Pediatr Blood Cancer 2005; 44:687-8.
5. Roozendaal KJ, de Valk B, ten Velden JJ, vander Woude HJ, Kroon BB. Alveolar soft-part sarcoma responding to interferon α-2b. BrJ Cancer 2003;89:243-5.
6. Kuriyama K,Todo S, Hibi S, Morimoto A, Imashuku S. Alveolar soft part sarcoma with lung metastases. Response to interferon α-2a? Med Pediatr Oncol 2001; 37:482-3.
7. Landanyi M, Lui MY, Antonescu CR, et al. The der(17)t(X;17)(p11;q25) of human alveolar soft part sarcoma fuses theTFE3 transcription factor gene to ASPL, a novel gene at 17q25. Oncogene 2001;20: 48-57.
8. Lazar AJ, Das P, Tuvin D, et al. Angiogenesis-promoting gene patterns in alveolar soft part sarcoma. Clin Cancer Res 2007;13:7314-21.
9. Tsuda M, Davis IJ, Argani P, et al. TFE3 fusions activate MET signaling by transcriptional up-regulation, defining another class of tumors as candidates for therapeutic MET inhibition. Cancer Res 2007;67:919-29.
10. Heinrich MC, Maki R, Corless CL, et al. Sunitinib (SU) response in imatinib-resistant (IM-R) GIST correlates with KIT and PDGFRA mutation status. Atlanta (GA): presented at the 42nd annual meeting of the American Society for Clinical Oncology;2006.
11. Morgan JA, Demetri GD, Fletcher JA, et al. Durable responses to SU11248 (sunitinib malate) are observed across all genotypes of imatinib mesylate resistant GIST. Paris (France): presented at the 17th International Congress on Anti Cancer Treatment; 2006.
12. Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006; 368:1329-38.
13. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356:115-24.
14. Motzer RJ,RiniBI, Bukowski RM,etal. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006;295:2516-24.
15. Mendel DB, Laird AD, Xin X, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2006;12:6203-4.
16. O'Farrell AM, Abrams TJ, Yuen HA, et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 2003;101:3597-605.
17. Chow LQ, Eckhardt SG. Sunitinib: from rational design to clinical efficacy. J Clin Oncol 2007;25:884-96.
18. Therasse P, Arbuck SG, Eisenhauer EA, et al.; European Organization for Research and Treatment of Cancer Institute of the United States, National Cancer Insitute of Canada. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205-6.
19. Young H, Baum R, Cremerius U, et al.; European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Measurement of clinical and subclinical tumour response using [18F]-fluoro-deoxyglucose and positron emission tomography:review and 1999 EORTC recommendations. Eur J Cancer 1999;35:1773-82.
20. Tamborini E, Casieri P, Miselli F, et al. Analysis of potential receptor tyrosine kinase targets in intimal and mural sarcomas. J Pathol 2007;212:227-35.
21. Borrello MG, Alberti L, Arighi E, et al. The full oncogenic activity of Ret/ptc2 depends on tyrosine 539, a docking site for phospholipase Cγ.Mol Cell Biol 1996;16:2151-63.
22. Moroni M, Veronese S, Benvenuti S, et al. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to anti-EGFR treatment in colorectal cancer: a cohort study. Lancet Oncol 2005;6:279-86.
23. Frattini M, Ferrario C, Bressan P, et al. Alternative mutations of BRAF, RET and NTRK1 are associated with similar but distinct gene expression patterns in papillary thyroid cancer. Oncogene 2004;23:7436-40.
24. Lagonigro MS, Tamborini E, Negri T, et al. PDGFRα PDGFRβ and KIT expression/activation in conventional chondrosarcoma. J Pathol 2006;208: 615-23.
25. Perrone F, Suardi S, Pastore E, et al. Molecular and cytogenetic subgroups of oropharyngeal squamous cell carcinoma. Clin Cancer Res 2006;12:6643-51. Erratum in: Clin Cancer Res 2007;13:4313.
26. Hirsch FR, Varella-Garcia M, McCoy J, et al. Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study. J Clin Oncol 2005;23:6838-45.
27. Chung CH, Ely K, McGavran L, et al. Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas. J Clin Oncol 2006;24: 4170-6.
28. Ivan M, Bond JA, Prat M, Comoglio PM,Wynford-Thomas D. Activated ras and ret oncogene induce overexpression of c-met (hepatocyte growth factor receptor) in human thyroid epithelial cells. Oncogene 1997;14:2417-23.
29. Shaw RJ, Cantley LC. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 2006; 441:424-30.
30. Smithey BE, Pappo AS, Hill DA. C-kit expression in pediatric solid tumors: a comparative immunohistochemical study. Am J Surg Pathol 2002;26: 486-92.
31. Ding S, Merkulova-Rainon T, Han ZC, Tobelem G. HGF receptor up-regolation contributes to the angiogenic phenotype of human endothelial cells and promotes angiogenesis in vitro. Blood 2003;101: 4816-22.
32. Wang SY, Chen B, Zhan YQ, et al. SU5416 is a potent inhibitor of hepatocyte growth factor receptor (c-Met) and blocks HGF-induced invasiveness of human HepG2 hepatoma cells. J Hepatol 2004;41: 267-73.
33. Liu P, Anderson RGW. Spatial organization of EGF receptor transmodulation by PDGF. Biochem Biophys Res Commun 1999;261:695-700.
34. Wada T, Qian XL, Greene MI. Intermolecular association of the p185neu protein and EGF receptor modulates EGF receptor function. Cell 1990;61: 1339-47.